NCT02272738View on ClinicalTrials.gov

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

April 30, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.

DRUG

Nab-Paclitaxel

Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.

Trial Locations (1)

537-8511

Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

All Listed Sponsors
lead

Osaka Medical Center for Cancer and Cardiovascular Diseases

OTHER

NCT02272738 - A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer | Biotech Hunter | Biotech Hunter